The SERPINF1 antibody is designed to target the SERPINF1 protein, also known as pigment epithelium-derived factor (PEDF), encoded by the SERPINF1 gene. PEDF belongs to the serine protease inhibitor (serpin) superfamily but lacks protease inhibitory activity. Instead, it is recognized for its multifunctional roles, including neurotrophic, anti-angiogenic, anti-tumorigenic, and anti-inflammatory properties. Structurally, PEDF is a secreted glycoprotein with a molecular weight of approximately 50 kDa, widely expressed in tissues such as the eye, liver, and adipose tissue.
SERPINF1 antibodies are critical tools in biomedical research for detecting and quantifying PEDF expression in various experimental models. They are used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study PEDF's involvement in diseases such as cancer, diabetic retinopathy, and age-related macular degeneration (AMD). In cancer, PEDF’s anti-angiogenic function suppresses tumor growth, while in ocular diseases, its neuroprotective effects help preserve retinal integrity.
Commercial SERPINF1 antibodies are typically raised in hosts like rabbits or mice, available as monoclonal or polyclonal forms. Validation for specificity and cross-reactivity is essential, as PEDF shares structural motifs with other serpins. Research using these antibodies has advanced understanding of PEDF’s dual role in tissue homeostasis and pathology, highlighting its therapeutic potential. For instance, modulating PEDF levels is being explored for treating neurodegenerative disorders and ocular neovascularization.